Psoriatic Arthritis

Twitter use revealed “early signals” of drug rationing and other critical behavior changes in patients with rheumatic diseases as they navigated the early months of the COVID-19 pandemic, according to data published in Rheumatology.

During the early months of the COVID-19 pandemic, increased all-cause mortality in patients with rheumatoid arthritis and other inflammatory joint diseases largely mirrored that of the general population, according to data.

More than half of patients with psoriatic arthritis experience a two-year delay from symptom onset to diagnosis, especially younger patients, those who are obese and those with enthesitis, noted data published in The Journal of Rheumatology.

Systemic inflammation burden and disease activity are independent risk factors for heart failure among patients with psoriatic disease, according to data published in Arthritis Care & Research.

Men with poor cardiorespiratory fitness levels during late adolescence were more likely to develop psoriasis or psoriatic arthritis later in life, according to a study.

The FDA has approved a label update for Janssen’s golimumab to include language that treatment alongside methotrexate improves fatigue in patients with active psoriatic arthritis and moderately to severely active rheumatoid arthritis.

Ixekizumab is efficacious in patients with psoriatic arthritis for up to 1 year, with or without concomitant methotrexate use, according to data published in Arthritis Research & Therapy.

Patients with nail psoriasis alongside psoriatic arthritis demonstrate worse disease activity, quality of life and work productivity than those without nail involvement, according to data published in The Journal of Rheumatology.

While novel drugs are changing the game in psoriatic arthritis, early diagnosis and interdisciplinary management remain keys to successful outcomes, according to a speaker at the Basic and Clinical Immunology for the Busy Clinician symposium.

Secukinumab is effective in psoriatic arthritis at 6 and 12 months, with significantly better remission, low disease activity, retention and response rates in patients naïve to disease-modifying antirheumatic drugs, according to data.